Following ASCO 2024, Toni Choueiri, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent updates from the EV-302 study investigating enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.
GU Cancer ASCO 2024 Highlights
Toni Choueiri, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in treatment paradigms for patients with genitourinary cancers.
Focusing on renal cell carcinoma, the Oncology Brothers and Toni Choueiri, MD, discuss KIM-1, a biomarker analysis in IMmotion010.
Medical oncologists discuss how real-world evidence from the IMDC is informing treatment decisions in GU cancer.
Toni Choueiri, MD, and the Oncology Brothers discuss the PSMAfore study evaluating health-related quality of life and pain in taxane-naïve patients with metastatic castration-resistant prostate cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
3
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
4
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
5